Receive curated updates on clinical research, medical education, key publications and Ferrer initiatives in rare neurological diseases. You can unsubscribe at any time.
Clinical Trials & Publications
-
ADORE Study Design
Explore publications from the ADORE Study Design, including the trial design and results of an international Phase 3, randomised, placebo-controlled study of daily oral edaravone (FNP122) in people living with ALS. -
ADOREXT Study
Explore publications from the ADOREXT Study, including the protocol design of an international Phase 3 open-label extension study investigating the long-term safety of daily oral edaravone (FNP-122) in ALS. -
ADORE Study Results
Read Ferrerʼs official press release on the top-line results from the Phase III ADORE study in ALS, including key findings on daily oral edaravone (FNP122), published on 10 January 2024.
Related ALS content
-
Medical Education
Explore educational resources designed to support healthcare professionals with up-to-date knowledge on ALS diagnosis, management and care.
-
Patient-focused initiatives
Discover patient-focused initiatives that raise awareness of ALS and support communication with patients and caregivers through practical resources.
